drugset / Trial / NCT00769899

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

NCT00769899

Phase 1 Completed 48 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase I randomized double-blind, placebo-controlled, single centre study to assess the safety, tolerability and pharmacokinetics of AZD7325 following single ascending dose administration to healthy male Japanese volunteers.

Timeline

Start
2008-10
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7325 Small molecule Oral

Indications

No indication recorded.